# Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment

> **NCT05152004** · NA · COMPLETED · sponsor: **Chang Gung Memorial Hospital** · enrollment: 240 (actual)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Pariet
- **DRUG:** Amolin
- **DRUG:** Klaricid
- **DRUG:** Flagyl

## Key facts

- **NCT ID:** NCT05152004
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-01
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-02-28
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152004, "Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05152004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*